{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T12:19:46Z","timestamp":1794226786349,"version":"4.9.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"DOI":"10.1186\/s13062-026-00854-9","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:53:49Z","timestamp":1781614429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ALDH1L2 suppresses ferroptosis-associated responses and reduces sunitinib sensitivity in renal cell carcinoma organoids"],"prefix":"10.1186","volume":"21","author":[{"given":"Xinming","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meizhou","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangtao","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changmin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianping","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangli","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"issue":"5","key":"854_CR1","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3390\/biomedicines12051111","volume":"12","author":"C Baston","year":"2024","unstructured":"Baston C, Parosanu AI, Stanciu I-M, Nitipir C. Metastatic kidney Cancer: Does the location of the metastases matter? Moving towards personalized therapy for metastatic renal cell carcinoma. Biomedicines. 2024;12(5):1111. https:\/\/doi.org\/10.3390\/biomedicines12051111.","journal-title":"Biomedicines"},{"key":"854_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jare.2024.04.032","volume":"70","author":"Z Wei","year":"2025","unstructured":"Wei Z, Ye Y, Liu C, Wang Q, Zhang Y, Chen K, et al. MIER2\/PGC1A elicits sunitinib resistance via lipid metabolism in renal cell carcinoma. J Adv Res. 2025;70:287\u2013305. https:\/\/doi.org\/10.1016\/j.jare.2024.04.032.","journal-title":"J Adv Res"},{"issue":"4","key":"854_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.4103\/ijc.IJC_380_17","volume":"54","author":"A Rudresha","year":"2017","unstructured":"Rudresha A, Chaudhuri T, Lakshmaiah KC, Babu G, Lokanatha D, Jacob L, et al. First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: a regional cancer center experience. Indian J Cancer. 2017;54(4):626\u201330. https:\/\/doi.org\/10.4103\/ijc.IJC_380_17.","journal-title":"Indian J Cancer"},{"issue":"2","key":"854_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115\u201324. https:\/\/doi.org\/10.1056\/NEJMoa065044.","journal-title":"N Engl J Med"},{"key":"854_CR5","first-page":"100929","volume-title":"Sunitinib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers","author":"J Jin","year":"2023","unstructured":"Jin J, et al. Sunitinib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers. Vol. 67. Drug Resist Updat; 2023. p. 100929."},{"key":"854_CR6","first-page":"54","volume":"8","author":"D Zirui","year":"2025","unstructured":"Zirui D, et al. Recent progress on tyrosine kinase inhibitors resistance in renal cell carcinoma: Another brick in the wall? Cancer Drug Resist. 2025;8:54.","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"854_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s13046-025-03534-0","volume":"44","author":"J Xing","year":"2025","unstructured":"Xing J, Li B, Wang S, Wang Z, Miao C. O-GlcNAcylation of UBAP2L regulates stress granule formation and sunitinib resistance in clear cell renal cell carcinoma. J Exp Clin Cancer Res. 2025;44(1):273. https:\/\/doi.org\/10.1186\/s13046-025-03534-0.","journal-title":"J Exp Clin Cancer Res"},{"key":"854_CR8","doi-asserted-by":"publisher","first-page":"1507574","DOI":"10.3389\/fphar.2024.1507574","volume":"15","author":"Y Hu","year":"2025","unstructured":"Hu Y, Tang J, Hong H, Chen Y, Ye B, Gao Z, et al. Ferroptosis in kidney disease: a bibliometric analysis from 2012 to 2024. Front Pharmacol. 2025;15:1507574. https:\/\/doi.org\/10.3389\/fphar.2024.1507574.","journal-title":"Front Pharmacol"},{"issue":"1","key":"854_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41392-024-01969-z","volume":"9","author":"Q Ru","year":"2024","unstructured":"Ru Q, Li Y, Chen L, Wu Y, Min J, Wang F. Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. Sig Transduct Target Ther. 2024;9(1):271. https:\/\/doi.org\/10.1038\/s41392-024-01969-z.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"854_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Sig Transduct Target Ther. 2024;9(1):55. https:\/\/doi.org\/10.1038\/s41392-024-01769-5.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"854_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12672-025-01911-x","volume":"16","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Wu X, Zhang J, Zhu M, Tian M, Zhao P. Advances in understanding ferroptosis mechanisms and their impact on immune cell regulation and tumour immunotherapy. Discov Onc. 2025;16(1):153. https:\/\/doi.org\/10.1007\/s12672-025-01911-x.","journal-title":"Discov Onc"},{"issue":"1","key":"854_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41420-023-01753-y","volume":"9","author":"J Wang","year":"2023","unstructured":"Wang J, Wu N, Peng M, Oyang L, Jiang X, Peng Q, et al. Ferritinophagy: research advance and clinical significance in cancers. Cell Death Discov. 2023;9(1):463. https:\/\/doi.org\/10.1038\/s41420-023-01753-y.","journal-title":"Cell Death Discov"},{"issue":"1","key":"854_CR13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41420-024-02116-x","volume":"10","author":"X Wu","year":"2024","unstructured":"Wu X, Cao J, Wan X, Du S. Programmed cell death in hepatocellular carcinoma: mechanisms and therapeutic prospects. Cell Death Discov. 2024;10(1):356. https:\/\/doi.org\/10.1038\/s41420-024-02116-x.","journal-title":"Cell Death Discov"},{"key":"854_CR14","doi-asserted-by":"publisher","first-page":"216247","DOI":"10.1016\/j.ccr.2024.216247","volume":"523","author":"MS Dar","year":"2025","unstructured":"Dar MS, Rosaiah P, Bhagyalakshmi J, Ahirwar S, Khan A, Tamizhselvi R, et al. Graphene quantum dots as nanotherapeutic agents for triple-negative breast cancer: insights from 3D tumor models. Coord Chem Rev. 2025;523:216247. https:\/\/doi.org\/10.1016\/j.ccr.2024.216247.","journal-title":"Coord Chem Rev"},{"issue":"1","key":"854_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40364-022-00421-0","volume":"10","author":"YY Yu","year":"2022","unstructured":"Yu YY, Zhu Y-J, Xiao Z-Z, Chen Y-D, Chang X-S, Liu Y-H, et al. The pivotal application of patient-derived organoid biobanks for personalized treatment of gastrointestinal cancers. Biomark Res. 2022;10(1):73. https:\/\/doi.org\/10.1186\/s40364-022-00421-0.","journal-title":"Biomark Res"},{"issue":"4","key":"854_CR16","doi-asserted-by":"publisher","first-page":"102683","DOI":"10.1016\/j.xpro.2023.102683","volume":"4","author":"A Skorda","year":"2023","unstructured":"Skorda A, Lauridsen AR, Huhtinen K, Lahtinen A, Senkowski W, Oikkonen J, et al. Quantification of cell death and proliferation of patient-derived ovarian cancer organoids through 3D imaging and image analysis. Star Protoc. 2023;4(4):102683. https:\/\/doi.org\/10.1016\/j.xpro.2023.102683.","journal-title":"Star Protoc"},{"issue":"7","key":"854_CR17","doi-asserted-by":"publisher","first-page":"101650","DOI":"10.1016\/j.xcrm.2024.101650","volume":"5","author":"A Vistoso Monreal","year":"2024","unstructured":"Vistoso Monreal A, Zhao H, Sedghizadeh PP, Lin D-C. Patient-derived tumor organoids to model drug response in gastric cancer. Cell Rep Med. 2024;5(7):101650. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101650.","journal-title":"Cell Rep. Med"},{"key":"854_CR18","doi-asserted-by":"publisher","unstructured":"Patel A, Cohen S, Moret R, Maresh G, Gobe GC, Li L. Patient-derived xenograft models to optimize kidney cancer therapies. Transl Androl Urol. 2019;8(Suppl S2):s156\u2013s165. https:\/\/doi.org\/10.21037\/tau.2018.11.04.","DOI":"10.21037\/tau.2018.11.04"},{"issue":"1","key":"854_CR19","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s10528-025-11045-y","volume":"64","author":"L Huang","year":"2026","unstructured":"Huang L, Liao C, Xiong Z, Chen Z, Zhang S. Hsa-miR-526b-5p regulates the sensitivity of colorectal Cancer to 5-fluorouracil by targeting TP53 in organoid models. Biochem Genet. 2026;64(1):660\u201383. https:\/\/doi.org\/10.1007\/s10528-025-11045-y.","journal-title":"Biochem Genet"},{"issue":"8","key":"854_CR20","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s41556-025-01713-x","volume":"27","author":"M Guo","year":"2025","unstructured":"Guo M, Wong IY, Moore AS, Medalia O, Lippincott-Schwartz J, Weitz DA, et al. Vimentin intermediate filaments as structural and Mechanical coordinators of mesenchymal cells. Nat Cell Biol. 2025;27(8):1210\u201318. https:\/\/doi.org\/10.1038\/s41556-025-01713-x.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"854_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/PAI.0000000000001256","volume":"33","author":"F Sheikh","year":"2025","unstructured":"Sheikh F, Fineberg S, Laurini J, Lanjewar S. Loss of Cytokeratin 7 (CK7) expression can be seen in significant proportion of solid papillary carcinoma of breast and associated invasive component. Appl Immunohistochem Mol Morphol. 2025;33(3):152\u201359. https:\/\/doi.org\/10.1097\/PAI.0000000000001256.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"854_CR22","unstructured":"Fu L, et al. TWF2 drives tumor progression and sunitinib resistance in renal cell carcinoma through hippo signaling suppression. Adv Sci. e06367."},{"issue":"1","key":"854_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41525-019-0092-9","volume":"4","author":"C Sarret","year":"2019","unstructured":"Sarret C, Ashkavand Z, Paules E, Dorboz I, Pediaditakis P, Sumner S, et al. Deleterious mutations in ALDH1L2 suggest a novel cause for neuro-ichthyotic syndrome. npj Genom Med. 2019;4(1):17. https:\/\/doi.org\/10.1038\/s41525-019-0092-9.","journal-title":"npj Genom Med"},{"issue":"5","key":"854_CR24","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/cge.14479","volume":"105","author":"M You","year":"2024","unstructured":"You M, Shamseldin HE, Fogle HM, Rushing BR, AlMalki RH, Jaafar A, et al. Further delineation of the phenotypic and metabolomic profile of ALDH1L2-related neurodevelopmental disorder. Clin Genet. 2024;105(5):488\u201398. https:\/\/doi.org\/10.1111\/cge.14479.","journal-title":"Clin Genet"},{"issue":"1","key":"854_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s13046-025-03490-9","volume":"44","author":"F Liu","year":"2025","unstructured":"Liu F, Li X, Zhang Y, Ge S, Shi Z, Liu Q, et al. Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma. J Exp Clin Cancer Res. 2025;44(1):227. https:\/\/doi.org\/10.1186\/s13046-025-03490-9.","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"854_CR26","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1158\/1535-7163.MCT-20-0423","volume":"19","author":"AS Dekhne","year":"2020","unstructured":"Dekhne AS, Hou Z, Gangjee A, Matherly LH. Therapeutic targeting of mitochondrial one-carbon metabolism in Cancer. Mol Cancer Ther. 2020;19(11):2245\u201355. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0423.","journal-title":"Mol Cancer Ther"},{"key":"854_CR27","doi-asserted-by":"publisher","unstructured":"Shen G, Liu J, Wang Y, Deng Z, Deng F. Ferroptosis in Cancer and inflammatory diseases: mechanisms and therapeutic implications. MedComm. 2025;6(9):e70349. https:\/\/doi.org\/10.1002\/mco2.70349.","DOI":"10.1002\/mco2.70349"},{"key":"854_CR28","unstructured":"Zheng D, et al. Targeting ferroptosis in nasopharyngeal carcinoma: mechanisms of therapy resistance and therapeutic opportunities. Adv Biol. e00460."},{"key":"854_CR29","doi-asserted-by":"publisher","first-page":"1629620","DOI":"10.3389\/fimmu.2025.1629620","volume":"16","author":"Z Shan","year":"2025","unstructured":"Shan Z, Liu F. Targeting ferroptosis, pyroptosis and necroptosis for cancer immunotherapy in melanoma: mechanistic insights and clinical perspectives. Front. Immunol. 2025;16:1629620. https:\/\/doi.org\/10.3389\/fimmu.2025.1629620.","journal-title":"Front. Immunol"},{"issue":"22","key":"854_CR30","doi-asserted-by":"publisher","first-page":"12340","DOI":"10.1021\/acs.jafc.4c00523","volume":"72","author":"M Zhang","year":"2024","unstructured":"Zhang M, Liu J, Yu Y, Liu X, Shang X, Du Z, et al. Recent Advances in the inhibition of membrane lipid peroxidation by Food-borne plant polyphenols via the Nrf2\/GPx4 pathway. J Agric Food Chem. 2024;72(22):12340\u201355. https:\/\/doi.org\/10.1021\/acs.jafc.4c00523.","journal-title":"J Agric Food Chem"},{"key":"854_CR31","doi-asserted-by":"publisher","first-page":"156925","DOI":"10.1016\/j.phymed.2025.156925","volume":"143","author":"W Liu","year":"2025","unstructured":"Liu W, Zhang J, Wu M, Ren D, Chen C, Du Z, et al. Ponicidin triggered ferroptosis in esophageal squamous cell carcinoma by suppressing the SLC7A11\/Glutathione\/GPX4 signalling axis. Phytomedicine. 2025;143:156925. https:\/\/doi.org\/10.1016\/j.phymed.2025.156925.","journal-title":"Phytomedicine"},{"issue":"30","key":"854_CR32","doi-asserted-by":"publisher","first-page":"23056","DOI":"10.1074\/jbc.M110.128843","volume":"285","author":"NI Krupenko","year":"2010","unstructured":"Krupenko NI, Dubard ME, Strickland KC, Moxley KM, Oleinik NV, Krupenko SA. ALDH1L2 is the mitochondrial homolog of 10-formyltetrahydrofolate dehydrogenase. J Biol Chem. 2010;285(30):23056\u201363. https:\/\/doi.org\/10.1074\/jbc.M110.128843.","journal-title":"J Biol Chem"},{"key":"854_CR33","doi-asserted-by":"publisher","unstructured":"Zhou M, Ma J, Tan Y, Zhao J, Li R, Tan R. Natural products as adjuvants to enhance the efficacy of immune checkpoint inhibitors in overcoming drug resistance and improving antitumor responses. Food Sci Hum Wellness. 2025. https:\/\/doi.org\/10.26599\/FSHW.2025.9250757.","DOI":"10.26599\/FSHW.2025.9250757"},{"issue":"10","key":"854_CR34","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.7150\/ijbs.113709","volume":"21","author":"Q Wang","year":"2025","unstructured":"Wang Q, Xue F, Assaraf YG, Lin Y. Harnessing Natural products to surmount drug resistance in gastric Cancer: mechanisms and therapeutic perspectives. Int. J. Biol. Sci. 2025;21(10):4604\u201328. https:\/\/doi.org\/10.7150\/ijbs.113709.","journal-title":"Int. J. Biol. Sci"},{"issue":"12","key":"854_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1934578X241290975","volume":"19","author":"H Liu","year":"2024","unstructured":"Liu H, Yu J, Dong Y, Rezeng C, Li X. Targeting arachidonic acid pathway with Natural ingredients from traditional Chinese medicine for Cancer prevention and therapy. Nat Prod Commun. 2024;19(12):12. https:\/\/doi.org\/10.1177\/1934578X241290975.","journal-title":"Nat Prod Commun"},{"key":"854_CR36","doi-asserted-by":"publisher","first-page":"107650","DOI":"10.1016\/j.toxicon.2024.107650","volume":"241","author":"S Cho","year":"2024","unstructured":"Cho S, Choi HJ, Song GY, Bae J-S. Therapeutic effects of hederacolchiside A1 on particulate matter-induced pulmonary injury. Toxicon. 2024;241:107650. https:\/\/doi.org\/10.1016\/j.toxicon.2024.107650.","journal-title":"Toxicon"},{"issue":"4","key":"854_CR37","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3390\/cancers15041272","volume":"15","author":"S Kim","year":"2023","unstructured":"Kim S, Lee K-H, Choi H-J, Kim E, Kang S, Han M, et al. Hederacolchiside A1 suppresses autophagy by inhibiting cathepsin C and reduces the growth of colon Cancer. Cancers (Basel). 2023;15(4):1272. https:\/\/doi.org\/10.3390\/cancers15041272.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"854_CR38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.20892\/j.issn.2095-3941.2025.0145","volume":"22","author":"G Li","year":"2025","unstructured":"Li G, Shi Q, Wu Q, Sui X. Target identification of natural products in cancer with chemical proteomics and artificial intelligence approaches. Cancer Biol Med. 2025;22(6):549\u201397. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2025.0145.","journal-title":"Cancer Biol Med"},{"issue":"4","key":"854_CR39","doi-asserted-by":"publisher","first-page":"045008","DOI":"10.1088\/1758-5090\/adecc5","volume":"17","author":"S Mao","year":"2025","unstructured":"Mao S, Xie R, Shou J, Pang Y, Sun W. Bioprinting of patient-derived heterogeneous renal cell carcinoma organoids for personalized therapy. Biofabrication. 2025;17(4):045008. https:\/\/doi.org\/10.1088\/1758-5090\/adecc5.","journal-title":"Biofabrication"},{"key":"854_CR40","doi-asserted-by":"publisher","unstructured":"Gu A, Li J, Li M-Y, Liu Y. Patient-derived xenograft model in cancer: establishment and applications. MedComm. 2025;6(2):e70059. https:\/\/doi.org\/10.1002\/mco2.70059.","DOI":"10.1002\/mco2.70059"},{"issue":"7","key":"854_CR41","doi-asserted-by":"publisher","first-page":"101627","DOI":"10.1016\/j.xcrm.2024.101627","volume":"5","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Li S, Zhu L, Huang M, Xie Y, Song X, et al. Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer. Cell Rep. Med. 2024;5(7):101627. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101627.","journal-title":"Cell Rep. Med"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-026-00854-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00854-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00854-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:39:23Z","timestamp":1788482363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13062-026-00854-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["854"],"URL":"https:\/\/doi.org\/10.1186\/s13062-026-00854-9","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from all patients providing samples, and the study was approved by the Ethics Committee of The Second Affiliated Hospital of Hainan Medical University (approval number LW2021643). All procedures involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.All animal protocols were approved by the committee of the The Ethical Committee of Guangzhou Forevergen Medical Laboratory Animal Center (approval number: IACUC-AEWC-F250801001). All animal experiments comply with the ARRIVE guidelines and be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010\/63\/EU for animal experiments.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"162"}}